2005/08/24[CML] Mitochondria-dependent apoptosis induced by a novel amphipathic photochemotherapeutic agent ZnPcS2P2 in HL60 cells.Rob 2005/08/24[CML] Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in ...
The Sokal index predicts survivalbased characteristics such as the patient’s age, spleen size on clinical examination, platelet count, and percentage of blasts in the peripheral blood. Depending on the Sokal score, patients are classified as having low-risk, intermediate-risk, or highrisk CML, w...
In addition, patients receiving nilotinib demonstrated a lower rate of progression to the accelerated or blast stage of CML. Also in this study, the 5-year OS and PFS were similar in both groups. [3] In patients who receive first-line therapy with TKIs, the rate of decline in BCR-ABL...
efficacy. The five-year survival rate for AML patients is 14%. New targeted approaches hold the potential to transform the treatment of AML: reducing side effects, improving tolerability and increasing the efficacy of chemotherapeutic regimens. In May 2000, Vertex and Novartis entered an alliance to...
survival prolongation, likely because of their potent efficacy and the availability of effective TKIs salvage therapies for patients who have a cytogenetic relapse with frontline TKI therapy. All four TKIs are equivalent if the aim of therapy is to improve survival. In younger patients with high‐...
MDA and H2O2, supporting the higher survival rates ofCmLOX10-OX plants than that of WT plants (Fig.3). Plants respond to drought stress from the cellular to the whole-plant level. Water loss is crucial for plant tolerance to drought stress36. The water loss rate was significantly higher ...
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23...
To date, 200 "first generation" autologous transplantsfor the treatment of CML have been performed at eight centersin Europe and North America. In this group of patients, the survivalrate (at a median of 4 years post-transplant) for those with chronicphase CML was 59%, Dr. McGlave reporte...
After the introduction of tyrosine kinase inhibitors (TKIs), the annual rate of progression from CML-CP to AP or BP dramatically decreased to 1–1.5% from more than 20% [1, 2]. However, the prognosis for adult patients with de novo or secondary CML-BP remains poor; median survival is ...
The progression rate was significantly lower in patients treated with IM than in those treated without IM (0 vs. 28.6%, p=0.006). In summary, the survival outcomes of pediatric patients with CML were dramatically improved by treatment with IM compared to HSCT. 展开 关键词: Chronic myeloid ...